Your browser doesn't support javascript.
loading
HEPATOCELLULAR CARCINOMA: CURRENT AND PROSPECTIVE IMMUNOTHERAPEUTIC STRATEGIES.
Kikodze, N; Mazmishvili, K; Iobadze, M; Rekhviashvili, Kh; Nanava, N; Pantsulaia, I; Mizandari, M; Janikashvili, N; Chikovani, T.
Afiliación
  • Kikodze N; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Mazmishvili K; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Iobadze M; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Rekhviashvili Kh; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Nanava N; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Pantsulaia I; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Mizandari M; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Janikashvili N; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
  • Chikovani T; Tbilisi State Medical University, Department of Immunology; Institute of Medical Biotechnology; Department of Radiology; Test-laboratory Ltd, Tbilisi; University of Burgundy, Faculty of Medicine, INSERM U1098,Dijon, France.
Georgian Med News ; (246): 78-84, 2015 Sep.
Article en En | MEDLINE | ID: mdl-26355320
Hepatocellular carcinoma (HCC) is a highly lethal and the most common primary liver cancer with increasing worldwide incidence. Pathogenesis of HCC is immune mediated, however, not completely understood. Chronic low-grade inflammation alters both innate and adaptive immune responses. As a result tolerogenic environment is established in damaged organ. Up to date, incomplete understanding of HCC pathogenesis and the extend of biomarker variability among patients represent the major obstacle for early diagnosis and for the choice of effective treatment. Among current treatment options for HCC, thermal ablation strategy, which in addition to cancer eradication provides adjuvant/"danger"signal to the patient's immune cells, has demonstrated its active immunotherapeutic effect. In ongoing phase I/II clinical trials, tumor antigen loaded dendritic cell (DC)-based vaccines as well as tumor-specific cytotoxic T cells are being tested. Genetically redirected T cell therapy and more refined autologous vaccines are still awaiting approaches in HCC. The topic of this review focuses on current and bench-to-bedside immunotherapeutic strategies for HCC and discusses their advantages and limitations in clinic. We also weight up several prospective immunotherapeutic approaches which in theory have the potential for further implication in HCC. Combination of the induction of effective antitumor immunity with the inhibition of the mechanisms of tumor-induced immunosuppression ought to be a key objective in these future developments.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Inmunidad Innata / Inmunoterapia / Neoplasias Hepáticas Tipo de estudio: Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Georgian Med News Asunto de la revista: MEDICINA Año: 2015 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Georgia
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Inmunidad Innata / Inmunoterapia / Neoplasias Hepáticas Tipo de estudio: Risk_factors_studies / Screening_studies Límite: Humans Idioma: En Revista: Georgian Med News Asunto de la revista: MEDICINA Año: 2015 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Georgia